However, whilst cancer was more common in our anti-NXP2 positive group in comparison to the rest of the cohort (13.5% vs 9.5% for CAM and 17.1% vs 14.2% for cancer-ever), this did not reach statistical significance. The gene discussed is MORC3; the disease is cancer.